Value of atherogenic index of plasma in predicting metabolic associated fatty liver disease in patients with type 2 diabetes mellitus

Mengya GAO; Qian QIN; Shoujun WANG

doi:10.3969/j.issn.1001-5256.2023.06.012

Volume 39 Issue 6

Jun. 2023

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(6): 1325-1331

PDF( 2586 KB)

Value of atherogenic index of plasma in predicting metabolic associated fatty liver disease in patients with type 2 diabetes mellitus

DOI: 10.3969/j.issn.1001-5256.2023.06.012

Mengya GAO^a,
Qian QIN^b,
Shoujun WANG^{a
,
,
,}

a.
Department of Endocrinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China
b.
Department of Physical Examination, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China

Research funding:

Science and Technology Research Project of Henan Province (212102310204)

More Information

Corresponding author: WANG Shoujun, wangshoujun02@126.com (ORCID: 0000-0002-0209-8545)
Received Date: 2022-12-01
Accepted Date: 2022-12-29
Published Date: 2023-06-20

Abstract

Abstract

Objective To investigate the association between atherogenic index of plasma (AIP) and metabolic associated fatty liver (MAFLD) in type 2 diabetes mellitus (T2DM). Methods A total of 375 patients with T2DM who were hospitalized and treated in Department of Endocrinology, The First Affiliated Hospital of Zhengzhou University, from September 2021 to September 2022 were enrolled, and according to the presence or absence of MAFLD, they were divided into T2DM+MAFLD group with 245 patients and T2DM group with 130 patients. Related clinical data were recorded, and AIP was calculated. According to the quartiles of AIP, the patients were divided into Q1 group (AIP≤0.20), Q2 group (0.20 < AIP≤0.24), Q3 group (0.24 < AIP≤0.48), and Q4 group (AIP > 0.48). The independent-samples t test was used for comparison of normally distributed continuous data between groups, and the Wilcoxon rank-sum test was used for comparison of non-normally distributed continuous data between groups; the trend chi-square test was used for the trend analysis of categorical data. The multivariate logistic regression analysis was used to investigate the effect of AIP on MAFLD, and the receiver operating characteristic (ROC) curve and the area under the ROC curve (AUC) were used to assess the value of the indicators such as AIP, body mass index (BMI), and alanine aminotransferase (ALT) in predicting T2DM with MAFLD. Results Compared with the T2DM group, the T2DM+MAFLD group had significant increases in BMI, systolic pressure, uric acid, fasting blood glucose, glycosylated hemoglobin, ALT, aspartate aminotransferase, gamma-glutamyl transpeptidase, alkaline phosphatase, triglyceride, low-density lipoprotein, and AIP and a significant reduction in high-density lipoprotein (all P < 0.05). The trend chi-square test showed that the prevalence rate of MAFLD in T2DM patients tended to increase with the increase in AIP level (χ_trend²=20.338, P < 0.05). The multivariate logistic regression analysis showed that compared with the Q1 group, the Q4 group had a significant increase in the risk of MAFLD (odds ratio =2.396, 95% confidence interval: 1.018-5.640, P=0.045). The ROC curve analysis showed that the diagnostic model of AIP combined with BMI and ALT had the best diagnostic performance (AUC=0.816), with a sensitivity of 70.2% and a specificity of 78.5% at the optimal cut-off value of 0.670. Conclusion AIP is an independent risk factor for MAFLD in T2DM patients, and AIP combined with BMI and ALT has a good predictive value for T2DM with MAFLD.
- Atherogenic Index of Plasma,
- Diabetes Mellitus, Type 2,
- Non-alcoholic Fatty Liver Disease

FullText(HTML)

References(22)

References

[1]	de ALWIS NM, DAY CP. Non-alcoholic fatty liver disease: the mist gradually clears[J]. J Hepatol, 2008, 48(Suppl 1): S104-S112. DOI: 10.1016/j.jhep.2008.01.009.
[2]	CHALASANI N, YOUNOSSI Z, LAVINE JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association[J]. Hepatology, 2012, 55(6): 2005-2023. DOI: 10.1002/hep.25762.
[3]	DOU KF, YANG XS. Surgeons should attach importance to the understanding of metabolic associated fatty liver disease[J]. Chin J Dig Surg, 2021, 20(1): 40-45. DOI: 10.3760/cma.j.cn115610-20201214-00780. 窦科峰, 杨西胜. 外科医师应重视对代谢相关脂肪性肝病的认识[J]. 中华消化外科杂志, 2021, 20(1): 40-45. DOI: 10.3760/cma.j.cn115610-20201214-00780.
[4]	XUE R, FAN JG. Brief introduction of an international expert consensus statement: A new definition of metabolic associated fatty liver disease[J]. J Clin Hepatol, 2020, 36(6): 1224-1227. DOI: 10.3969/j.issn.1001-5256.2020.06.007. 薛芮, 范建高. 代谢相关脂肪性肝病新定义的国际专家共识简介[J]. 临床肝胆病杂志, 2020, 36(6): 1224-1227. DOI: 10.3969/j.issn.1001-5256.2020.06.007.
[5]	YOUNOSSI ZM, GOLABI P, de AVILA L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis[J]. J Hepatol, 2019, 71(4): 793-801. DOI: 10.1016/j.jhep.2019.06.021.
[6]	FERNÁNDEZ-MACÍAS JC, OCHOA-MARTÍNEZ AC, VARELA-SILVA JA, et al. Atherogenic index of plasma: Novel predictive biomarker for cardiovascular illnesses[J]. Arch Med Res, 2019, 50(5): 285-294. DOI: 10.1016/j.arcmed.2019.08.009.
[7]	CHANG Y, LI Y, GUO X, et al. The association of ideal cardiovascular health and atherogenic index of plasma in rural population: A cross-sectional study from Northeast China[J]. Int J Environ Res Public Health, 2016, 13(10): 1027. DOI: 10.3390/ijerph13101027.
[8]	LIU H, LIU K, PEI L, et al. Atherogenic index of plasma predicts outcomes in acute ischemic stroke[J]. Front Neurol, 2021, 12: 741754. DOI: 10.3389/fneur.2021.741754.
[9]	World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus[R]. World health organization, 1999.
[10]	XIE J, YANG M, XING Y. Effects of liraglutide on glucose and lipid metabolism and insulin resistance in type 2 diabetes mellitus patients with non-alcoholic fatty liver disease[J/CD]. Chin J Liver Dis (Electronic Version), 2021, 13(4): 46-53. DOI: 10.3969/j.issn.1674-7380.2021.04.008. 谢晶, 杨淼, 邢英. 利拉鲁肽对2型糖尿病合并非酒精性脂肪性肝病患者糖脂代谢及胰岛素抵抗的影响[J/CD]. 中国肝脏病杂志(电子版), 2021, 13(4): 46-53. DOI: 10.3969/j.issn.1674-7380.2021.04.008.
[11]	ZHOU F, ZHOU J, WANG W, et al. Unexpected rapid increase in the burden of NAFLD in China From 2008 to 2018: A systematic review and meta-analysis[J]. Hepatology, 2019, 70(4): 1119-1133. DOI: 10.1002/hep.30702.
[12]	DEWIDAR B, KAHL S, PAFILI K, et al. Metabolic liver disease in diabetes - From mechanisms to clinical trials[J]. Metabolism, 2020, 111S: 154299. DOI: 10.1016/j.metabol.2020.154299.
[13]	XIE F, ZHOU H, WANG Y. Atherogenic index of plasma is a novel and strong predictor associated with fatty liver: a cross-sectional study in the Chinese Han population[J]. Lipids Health Dis, 2019, 18(1): 170. DOI: 10.1186/s12944-019-1112-6.
[14]	SAMIMI S, RAJABZADEH S, RABIZADEH S, et al. Atherogenic index of plasma is an independent predictor of metabolic-associated fatty liver disease in patients with type 2 diabetes[J]. Eur J Med Res, 2022, 27(1): 112. DOI: 10.1186/s40001-022-00731-x.
[15]	SCHREUDER TC, VERWER BJ, van NIEUWKERK CM, et al. Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment[J]. World J Gastroenterol, 2008, 14(16): 2474-2486. DOI: 10.3748/wjg.14.2474.
[16]	STEFAN N, KANTARTZIS K, HÄRING HU. Causes and metabolic consequences of fatty liver[J]. Endocr Rev, 2008, 29(7): 939-960. DOI: 10.1210/er.2008-0009.
[17]	POSTIC C, GIRARD J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice[J]. J Clin Invest, 2008, 118(3): 829-838. DOI: 10.1172/JCI34275.
[18]	ABBASI F, REAVEN GM. Comparison of two methods using plasma triglyceride concentration as a surrogate estimate of insulin action in nondiabetic subjects: triglycerides×glucose versus triglyceride/high-density lipoprotein cholesterol[J]. Metabolism, 2011, 60(12): 1673-1676. DOI: 10.1016/j.metabol.2011.04.006.
[19]	DONG BY, MAO YQ, LI ZY, et al. The value of the atherogenic index of plasma in non-obese people with non-alcoholic fatty liver disease: a secondary analysis based on a cross-sectional study[J]. Lipids Health Dis, 2020, 19(1): 148. DOI: 10.1186/s12944-020-01319-2.
[20]	FRACANZANI AL, PETTA S, LOMBARDI R, et al. Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity[J]. Clin Gastroenterol Hepatol, 2017, 15(10): 1604-1611. e1. DOI: 10.1016/j.cgh.2017.04.045.
[21]	GAWRIEH S, WILSON LA, CUMMINGS OW, et al. Histologic findings of advanced fibrosis and cirrhosis in patients with nonalcoholic fatty liver disease who have normal aminotransferase levels[J]. Am J Gastroenterol, 2019, 114(10): 1626-1635. DOI: 10.14309/ajg.0000000000000388.
[22]	CHEN JF, QIN Q, WU ZQ, et al. A cohort study on the correlation between alanine aminotransferase trajectories and new-onset metabolic fatty liver disease[J]. Chin J Epidemiol, 2022, 43(2): 234-240. DOI: 10.3760/cma.j.cn112338-20210809-00621. 陈静锋, 秦迁, 吴卓青, 等. 谷丙转氨酶轨迹与新发代谢相关脂肪性肝病相关性的队列研究[J]. 中华流行病学杂志, 2022, 43(2): 234-240. DOI: 10.3760/cma.j.cn112338-20210809-00621.

Relative Articles

[1]	Xin DAI, Hanlin LIU, Long CHENG, Zhulin LUO, Tao WANG. Association of programmed death-1 and programmed death-ligand 1 with the prognosis and clinical features of patients with hepatocellular carcinoma: A meta-analysis[J]. Journal of Clinical Hepatology, 2022, 38(7): 1577-1583. doi: 10.3969/j.issn.1001-5256.2022.07.022
[2]	Pan LIU, Liang HAO, Yu CHENG, Beibei YANG, Yong WEI, Zhenhong XIA, Shoujun YU. Advances in the application of ultrasound in the diagnosis and treatment of acute pancreatitis[J]. Journal of Clinical Hepatology, 2022, 38(12): 2873-2876. doi: 10.3969/j.issn.1001-5256.2022.12.037
[3]	Xiangliu OUYANG, Yunxia HAN, Lichun ZHENG, Yingchun ZHAO, Xinyu SHEN, Wenjun ZHANG, Yanbin WANG. Ultrasound findings and contrast-enhanced ultrasound findings of mass-type autoimmune pancreatitis versus pancreatic ductal adenocarcinoma[J]. Journal of Clinical Hepatology, 2022, 38(6): 1351-1355. doi: 10.3969/j.issn.1001-5256.2022.06.025
[4]	Quan ZHOU, Lihui YANG, Fangqing JIANG. Long-term prognosis of patients with hepatitis C virus-related hepatocellular carcinoma receiving direct-acting antiviral: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(8): 1836-1840. doi: 10.3969/j.issn.1001-5256.2021.08.018
[5]	Minjun LI, Zhujian DENG, Haotian LIU, Yuxian TENG, Rongrui HUO, Xiumei LIANG, Bangde XIANG, Lequn LI, Jianhong ZHONG. Clinical effect of re-hepatic resection versus radiofrequency ablation in treatment of recurrent hepatocellular carcinoma in Asia: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(5): 1103-1109. doi: 10.3969/j.issn.1001-5256.2021.05.025
[6]	Yisheng PENG, Pan HE, Gang ZHU, Xinkai LI, Shunde TAN, Jianfei CHEN, Jun FAN, Bin LUO, Song SU, Bo LI, Xiaoli YANG. Efficacy and safety of CalliSpheres microsphere versus conventional transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(8): 1841-1847. doi: 10.3969/j.issn.1001-5256.2021.08.019
[7]	Ying LIU, Benjian GAO, Xiaoli YANG, Cheng FANG, Song SU, Bo LI. Effect of hemihepatic vascular exclusion versus total hepatic vascular exclusion in hepatectomy for primary liver cancer: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(1): 73-78. doi: 10.3969/j.issn.1001-5256.2021.01.015
[8]	Shun ZHU, Zhiguo LI, Shuo LI, Xu CAO, Xiaobin LI, Xiaoke LI, Yongan YE. Effect of aspirin on the incidence rate of liver cancer in patients with viral hepatitis: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(5): 1097-1102. doi: 10.3969/j.issn.1001-5256.2021.05.024
[9]	Sun DongXue, Yang Zhu, Long FengXi, Wei XianMan, Tang DongXin. Efficacy and safety of Kanglaite injection combined with transarterial chemoembolization in treatment of advanced liver cancer: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(2): 363-368. doi: 10.3969/j.issn.1001-5256.2020.02.026
[10]	Qian Le, Ying Li. Selection of second-line drugs for adult autoimmune hepatitis: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(9): 2015-2020. doi: 10.3969/j.issn.1001-5256.2020.09.021
[11]	Zhou ZiDong, Li RenLi, Chen Kai, Zhang WenCheng, Xia ShiHai. Clinical effect of epidermal growth factor receptor-targeted agents in treatment of advanced pancreatic cancer:A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(5): 1097-1103. doi: 10.3969/j.issn.1001-5256.2020.05.029
[12]	Zi Li, Chen Kai, Liu GuangLin, Li RenLi, Xu Wei. Clinical effect of gemcitabine combined with high-intensity focused ultrasound in treatment of advanced pancreatic cancer: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(1): 153-157. doi: 10.3969/j.issn.1001-5256.2020.01.034
[13]	Li Dong, Luo TianYang, Ran YaWei. Value of contrast-enhanced computed tomography and magnetic resonance imaging in diagnosis of residual or recurrent lesion after transcatheter arterial chemoembolization in hepatocellular carcinoma:A Meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(10): 2214-2219. doi: 10.3969/j.issn.1001-5256.2019.10.017
[14]	Wang YiBin, Liao JinTang, Xie LuLu, Qi WenJun, Chen LuYang, Li YueYi. Predictive value of preoperative ultrasound examination for factors associated with early postoperative recurrence of hepatocellular carcinoma after surgical resection [J]. Journal of Clinical Hepatology, 2015, 31(12): 2061-2065. doi: 10.3969/j.issn.1001-5256.2015.12.018
[15]	Liu LingFeng, Lu HaiYing, Yu YanYan, Wu ChiHong, Tian XiuLan. A comparative study of FibroScan and B ultrasound in diagnosis of liver fibrosis[J]. Journal of Clinical Hepatology, 2014, 30(10): 1045-1049. doi: 10.3969/j.issn.1001-5256.2014.10.018
[16]	Group of Pancreas Surgery, Chinese Society of Surgery, Chinese Medical Association. Guidelines for the management of pancreatic cancer (2014)[J]. Journal of Clinical Hepatology, 2014, 30(12): 1240-1245. doi: 10.3969/j.issn.1001-5256.2014.12.003
[17]	Li ChunSheng, Ni CanRong. Expression of S100A4 and E-cadherin in pancreatic carcinoma and their relationship study[J]. Journal of Clinical Hepatology, 2006, 22(3): 207-208.
[18]	Ren Ben, Song JiangBo, Zhang FenQin, Si HongXia, Gao XuanXia. Stereotactic radiotherapy in 206 patients with pancreatic carcinoma[J]. Journal of Clinical Hepatology, 2006, 22(1): 52-53.
[20]	Yuan ZhangJi, Yang Lei, Yao Cheng, Wang GuanJun. Observation of high intensity focused ultrasound treating 40 cases of cancer of pancreas[J]. Journal of Clinical Hepatology, 2003, 19(3): 145-146.

Supplements(0)

Cited By

Cited by

Periodical cited type(37)

1.	李容容，苟悦，刘宁宁，陈日润，孙鑫，刘成海. 基于临床数据挖掘的中药对抗肿瘤药物相关肝损伤的影响及用药规律探讨. 时珍国医国药. 2024(01): 243-247 .
2.	张倩茹，卢颖，张婉婷，杨艳. 某院急性白血病患者药源性肝损伤临床治疗的回顾性分析. 遵义医科大学学报. 2024(04): 401-407 .
3.	中华医学会，中华医学会杂志社，中华医学会肝病分会药物性肝病学组，中华医学会全科医学分会，中华医学会《中华全科医师杂志》编辑委员会，中国医药生物技术协会药物性肝损伤防治技术专业委员会，中国初级卫生保健基金会药物肝脏安全性专业委员会，中国药物性肝损伤基层诊疗与管理指南制定专家组. 中国药物性肝损伤基层诊疗与管理指南(2024年). 中华全科医师杂志. 2024(08): 813-830 .
4.	郑晖，孙蓉. 药物联合应用对中草药相关肝损伤的影响. 临床肝胆病杂志. 2024(08): 1519-1524 . 本站查看
5.	李容容，李盟，苟悦，罗琼，吕桦，孙鑫，刘成海. 113例抗肿瘤药物相关肝损伤的临床特点及危险因素分析. 中国药物警戒. 2023(05): 505-510 .
6.	中国医药生物技术协会药物性肝损伤防治技术专业委员会，中华医学会肝病学分会药物性肝病学组. 中国药物性肝损伤诊治指南(2023年版). 中华肝脏病杂志. 2023(04): 355-384 .
7.	程诗思，杨成明，曾安津. 荆州地区结核病专科医院抗结核药物不良反应分析. 临床合理用药. 2023(22): 147-150 .
8.	江程，李春晓，杨玉晴，郭静. 热毒宁注射液上市后临床安全性文献研究. 中国药事. 2023(11): 1252-1265 .
9.	王双双，熊清芳，胡一帆，陈妙洋，杨永峰. 药物性肝损伤的临床与病理特点分析. 肝脏. 2023(11): 1280-1284 .
10.	孟尧，张萌萌，郭甜甜，赵新颜. 《中国药物性肝损伤诊治指南（2023年版）》更新要点解读. 中国肝脏病杂志(电子版). 2023(04): 1-5 .
11.	马世武，刘成海，刘晓琰，苏明华，李东良，李异玲，陈公英，陈军，陈金军，茅益民，赵景民，郭晓燕，唐洁婷，诸葛宇征，谢青，谢雯，赖荣陶，蔡大川，蔡庆贤. 中国药物性肝损伤诊治指南（2023年版）. 胃肠病学. 2023(07): 397-431 .
12.	孙晓楠，吕萌，程国亭. 药物性肝损伤139例回顾性分析. 中南医学科学杂志. 2022(03): 391-394 .
13.	李娜. 肺癌患者化疗后药物性肝损伤的临床特点. 中国医药指南. 2022(16): 22-25 .
14.	劳明珠. 异甘草酸镁治疗抗肿瘤药物引起的急性药物性肝损伤临床效果和安全性. 临床合理用药杂志. 2022(17): 84-87 .
15.	马万龙，焦运，张旭，丁向春，张平，欧阳花，王梦甜，张乐，徐灵博，杨安宁，姜怡邓. 血清IL-6在人工肝治疗药物性肝损伤预后评估中的价值. 宁夏医科大学学报. 2022(06): 622-629 .
16.	沈婷婷，李光耀，罗琼，李盟，孙鑫，陶艳艳，周祖山，刘成海. 类风湿性关节炎患者应用雷公藤制剂及合并用药所致药物性肝损伤的临床特征分析. 临床肝胆病杂志. 2022(09): 2067-2072 . 本站查看
17.	马世武，刘成海，刘晓琰，苏明华，李东良，李异玲，陈公英，陈军，陈金军，茅益民，赵景民，郭晓燕，唐洁婷，诸葛宇征，谢青，谢雯，赖荣陶，蔡大川，蔡庆贤. 中国药物性肝损伤诊治指南（2023年版）. 胃肠病学. 2022(06): 341-375 .
18.	汪涛，王学伟，蒋元烨，曹勤，季光. 162例药物性肝损伤患者分析. 肝脏. 2021(03): 243-246 .
19.	王艳，王昱，王岚，田秋菊，杨瑞园，李柯鑫，刘立伟，王晓明，王宇，欧晓娟，贾继东，赵新颜. 中草药与西药致药物性肝损伤的临床特征及其预后的对比研究. 肝脏. 2021(04): 364-369 .
20.	杨焕芝，李兴德，陈学平，张仲安，钱彦华，蒋潇，徐艳琼，宋沧桑. 93例药物性肝损伤患者临床特征分析. 中国药业. 2021(15): 122-125 .
21.	何婷婷，王丽苹，任璐彤，崔延飞，柏兆方，郭玉明，宫嫚，王睿林. 中西药肝损伤临床及病理特征分析. 肝脏. 2021(09): 962-967 .
22.	刘秀兰，李为，郭敏，杜金凤，刘东，李娟. 药物性肝损伤相关医疗损害案例分析. 药物流行病学杂志. 2021(11): 729-734 .
23.	陈凯霞，赵广玉，印登阳，陈宏俊，黄继勋. 三种保肝药治疗化疗引起的DILI的药物经济学评价. 中国实用医药. 2021(35): 188-191 .
24.	罗琼，朱哿瑞，顾宏图，刘坤，陈高峰，邢枫，陶艳艳，刘成海. 50例中草药与西药致药物性肝损伤患者的肝组织病理学特点比较. 临床肝胆病杂志. 2020(03): 596-601 . 本站查看
25.	蔡春梅. 妊娠早期肝功能异常60例的病因分析及干预. 中国城乡企业卫生. 2020(06): 100-102 .
26.	周力. 中西药所致药物性肝损伤临床及病理特点研究. 临床医药文献电子杂志. 2020(39): 56 .
27.	纪童童，陆海英，谭宁，于岩岩，徐小元. 急、慢性药物性肝损伤临床特征的对比分析. 临床肝胆病杂志. 2020(07): 1556-1561 . 本站查看
28.	何文昌，张克恭，赵凡惠，郭芮杉，高禄化，黄长形，王临旭. 290例药物性肝损伤患者临床特征分析. 实用肝脏病杂志. 2020(04): 540-543 .
29.	李梁，陶应敏，张学敏，谢娟，陈园. 药物性肝损伤患者外周血清HIF1α和COX-2定量检测的临床价值. 肝脏. 2020(08): 848-852 .
30.	李卉，张宏亮，杨天燕，黄振光，刘滔滔，韦芳. 我院125例抗结核药物不良反应报告分析. 中国医药导报. 2020(29): 151-154 .
31.	姜正艳，郑亮. 异甘草酸镁治疗药物性肝损伤临床疗效观察. 世界最新医学信息文摘. 2019(07): 123 .
32.	张惠娟，史祖宣，赵兰芳，高天慧，李健. 56例抗肿瘤药物致肝损伤临床特点分析. 临床肝胆病杂志. 2019(03): 574-578 . 本站查看
33.	梁栋，董晓锋，张燕，朱晓红，王建斌，刘妲妲，柳伟伟，方圆，王全楚. 98例药物性肝损伤的临床特点及诊疗体会. 肝脏. 2019(04): 389-391 .
34.	黄波，张炜. 喜炎平注射液联合还原型谷胱甘肽治疗重症烧伤后急性肝功能损伤临床研究. 创伤与急危重病医学. 2019(03): 156-159 .
35.	郭立杰，张海丛，叶立红，王超，杜婧，伍彦辉. 中西药所致药物性肝损伤临床及病理特点分析. 临床误诊误治. 2019(08): 28-33 .
36.	吴宇宇，袁苏榆，孙四珍，王岁晶，丁洋. 药物性肝损伤诊断治疗进展概述. 药物流行病学杂志. 2018(08): 550-555 .
37.	王建青，叶珺，郜玉峰，杨利琦. 106例药物性肝损伤患者用药回顾性调查. 中国医院药学杂志. 2018(18): 1967-1970 .